Objectives: Multi-drug resistant bacteria have been implicated in various debilitating infections that have led to life loss. This study developed an approach to tackle multidrug resistant Acinetobacter baumannii infection in a chronic wound model through A. baumannii phage encapsulation with resuspension in hydrogel. Materials and Methods: Two isolates of A. baumannii-specific lytic phases ɸAB140 and ɸAB150 alone, in combination (cocktail) encapsulated within a chitosan (CS) microparticle was suspended in CS hydrogel and evaluated for their therapeutic efficacy to ensure bacterial clearance in A. baumannii induced diabetic wound infection. Microencapsulation of the phage was carried out using ionic gelation techniques Biological characterization via cell cytoxicity, in vivo wound healing, histology and histomorphometry was carried out. Results: Two characterized A. baumannii phages (ɸAB140 and ɸAB150), specific to twenty A. baumannii isolates, were isolated. The encapsulated CS microparticle hydrogel exhibited a pH of 5.77 ± 0.05. The wound size reduction was most pronounced in formulation C2, which showed statistically significant wound seize reduction on days 4 and 7, 56.79 ± 2.02% and 62.15 ± 5.11%, respectively. The optimized concentration of C2 was not toxic to the cells as it adequately supported cell growth with a proliferation rate of 215 ± 7.89% compared to control (107.32 ± 4.55%). Conclusion: Microparticle carrier technology was used to show the lytic activity against multi drug-resistant A. baumannii. In vivo results showed significant wound size reduction that was most pronounced in formulation C2 on day 4.
Objectives: Multi-drug resistant bacteria have been implicated in various debilitating infections that have led to life loss. This study developed an approach to tackle multidrug resistant Acinetobacter baumannii infection in a chronic wound model through A. baumannii phage encapsulation with resuspension in hydrogel. Materials and Methods: Two isolates of A. baumannii-specific lytic phases ɸAB140 and ɸAB150 alone, in combination (cocktail) encapsulated within a chitosan (CS) microparticle was suspended in CS hydrogel and evaluated for their therapeutic efficacy to ensure bacterial clearance in A. baumannii induced diabetic wound infection. Microencapsulation of the phage was carried out using ionic gelation techniques Biological characterization via cell cytoxicity, in vivo wound healing, histology and histomorphometry was carried out. Results: Two characterized A. baumannii phages (ɸAB140 and ɸAB150), specific to twenty A. baumannii isolates, were isolated. The encapsulated CS microparticle hydrogel exhibited a pH of 5.77 ± 0.05. The wound size reduction was most pronounced in formulation C2, which showed statistically significant wound seize reduction on days 4 and 7, 56.79 ± 2.02% and 62.15 ± 5.11%, respectively. The optimized concentration of C2 was not toxic to the cells as it adequately supported cell growth with a proliferation rate of 215 ± 7.89% compared to control (107.32 ± 4.55%). Conclusion: Microparticle carrier technology was used to show the lytic activity against multi drug-resistant A. baumannii. In vivo results showed significant wound size reduction that was most pronounced in formulation C2 on day 4.
Entities:
Keywords:
chronic wound; cytotoxicity; microparticle hydrogel; ɸAB140 and ɸAB150 phage
Authors: Rolf Lood; Benjamin Y Winer; Adam J Pelzek; Roberto Diez-Martinez; Mya Thandar; Chad W Euler; Raymond Schuch; Vincent A Fischetti Journal: Antimicrob Agents Chemother Date: 2015-01-20 Impact factor: 5.191
Authors: Jean-Paul Pirnay; Bob G Blasdel; Laurent Bretaudeau; Angus Buckling; Nina Chanishvili; Jason R Clark; Sofia Corte-Real; Laurent Debarbieux; Alain Dublanchet; Daniel De Vos; Jérôme Gabard; Miguel Garcia; Marina Goderdzishvili; Andrzej Górski; John Hardcastle; Isabelle Huys; Elizabeth Kutter; Rob Lavigne; Maia Merabishvili; Ewa Olchawa; Kaarle J Parikka; Olivier Patey; Flavie Pouilot; Gregory Resch; Christine Rohde; Jacques Scheres; Mikael Skurnik; Mario Vaneechoutte; Luc Van Parys; Gilbert Verbeken; Martin Zizi; Guy Van den Eede Journal: Pharm Res Date: 2015-01-14 Impact factor: 4.200
Authors: Joan Colom; Mary Cano-Sarabia; Jennifer Otero; Javier Aríñez-Soriano; Pilar Cortés; Daniel Maspoch; Montserrat Llagostera Journal: Sci Rep Date: 2017-01-25 Impact factor: 4.379